Metronidazole Dawa

Metronidazole, the active ingredient in Metronidazole Dawa, is a nitroimidazole antibiotic presented as an oral dosage form for oral use. It treats a range of anaerobic bacterial and protozoal infections in adult patients and is prescribed by qualified healthcare professionals.

GNH USA supplies Metronidazole Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole Dawa is a nitroimidazole antibiotic used to treat infections caused by anaerobic bacteria and certain protozoa.

- Bacterial vaginosis: eliminates the anaerobic bacteria responsible for the condition, relieving discharge and odor. - Trichomoniasis: eradicates Trichomonas vaginalis, curing the infection and preventing recurrence. - Amoebiasis: destroys Entamoeba histolytica trophozoites, treating intestinal and extra‑intestinal disease. - Anaerobic bacterial infections: targets intra‑abdominal, skin and soft‑tissue infections caused by obligate anaerobes. - Clostridioides difficile infection (adjunct): reduces toxin‑producing bacteria when used alongside standard therapy.

Metronidazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Diarrhea: loose stools that resolve after therapy. - Abdominal discomfort: cramping or pain in the abdomen.

Serious or Rare Side Effects: - Seizures: neurological events requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: anaphylaxis, rash, or swelling of the face and throat.

Before initiating therapy, clinicians should consider several safety measures.

- Renal function assessment: adjust dose in patients with impaired kidney function. - Avoid alcohol: concurrent intake can cause a disulfiram‑like reaction. - Hepatic impairment caution: monitor liver enzymes in patients with liver disease. - Neuropathy monitoring: discontinue if signs of peripheral neuropathy appear. - Pregnancy and breastfeeding: use only if the potential benefit outweighs the unknown risk. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Metronidazole can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium serum concentrations, leading to toxicity. - Disulfiram: additive disulfiram‑like reactions.

Moderate Interactions (Monitor Closely): - Cimetidine: can increase metronidazole plasma levels. - Phenytoin: may reduce metronidazole concentrations, lowering effectiveness. - Oral contraceptives: may reduce hormonal efficacy, requiring additional contraception.